荃信生物-B(02509):QX030N/CLD-423完成I期临床试验首批受试者给药 CALDERA THERAPEUTICS累计筹资1.125亿美元

智通财经
Jan 14

智通财经APP讯,荃信生物-B(02509)公布,靶向经临床验证的IL-23p19及TL1A通路的双特异性抗体QX030N/CLD-423的I期健康志愿者试验已完成首批受试者给药。

截至本公告日期,公司QX030N/CLD-423的合作伙伴Caldera Therapeutics, Inc. (Caldera Therapeutics)累计完成融资1.125亿美元。 于2025年4月,Caldera Therapeutics从Atlas Venture、LAV及venBio获得7500万美元的A轮融资,近期则完成由Omega Funds领投的3750万美元A-1轮融资,参与的新投资者包括Wellington Management及Janus Henderson Investors。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10